"Unique_ID","ECOG_0","ECOG_1","ECOG_2","ECOG_3","ECOG_4","N_Patient","Pub_Year","FRAC_MALE","AGE_MED","Prop_Visceral","OS","PFS","Arm.Name","Title","Arm_Type","Rand_Group"
"ACKLA0201_T1",0.34,0.56,0.1,0,0,223,2001,0,56,0.57,20.1,NA,"CEF","Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study","experiment",""
"ACKLA0201_T2",0.36,0.54,0.1,0,0,237,2001,0,55,0.6,18.2,NA,"CMF","Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study","control",""
"ALBAI0808_T1",NA,NA,NA,NA,NA,261,2008,0,53,0.729,18.6,5.9,"Gemcitabine / Paclitaxel","Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment","experiment",""
"ALBAI0808_T2",NA,NA,NA,NA,NA,260,2008,0,53,0.73,15.8,3.9,"Paclitaxel","Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment","control",""
"ANDER0199_T1",0.545,0.292,0.11,0.052,0,161,1999,0,58,0.35,20.8,NA,"CAF+TAM","Doxorubicin Versus Methotrexate Both Combined with Cyclophosphamide, 5-Fluorouracil and Tamoxifen in Postmenopausal Patients with Advanced Breast Cancer - a Randomised Study with more than 10 Years Follow-up from the Danish Breast Cancer Cooperative Group","experiment",""
"ANDER0199_T2",0.534,0.328,0.103,0.034,0,180,1999,0,58,0.45,17.4,NA,"CMF+TAM","Doxorubicin Versus Methotrexate Both Combined with Cyclophosphamide, 5-Fluorouracil and Tamoxifen in Postmenopausal Patients with Advanced Breast Cancer - a Randomised Study with more than 10 Years Follow-up from the Danish Breast Cancer Cooperative Group","control",""
"ARPIN0203_T1",0.519,0.361,0.12,0,0,108,2003,0,59,NA,NA,NA,"Idoxifene","Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer","experiment",""
"ARPIN0203_T2",0.477,0.423,0.099,0,0,111,2003,0,57,NA,NA,NA,"Tamoxifen","Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer","control",""
"BACHE0711_T1",0.33,0.61,0.06,0,0,33,2011,0,57,NA,36.4,12.4,"XT","Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer","experiment",""
"BACHE0711_T2",0.32,0.65,0.03,0,0,35,2011,0,59,NA,26.6,6.8,"ET","Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer","control",""
"BACHE0812_T1",0.426,0.519,0.056,0,0,57,2012,0,66,0.49,32.9,NA,"Tamoxifen Alone","Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study","control",""
"BACHE0812_T2",0.604,0.34,0.057,0,0,54,2012,0,63,0.57,NA,NA,"Tamoxifen Plus Everolimus","Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study","experiment",""
"BARRI0510_T1",0.612,0.371,0.017,0,0,238,2010,0,53,0.73,15.3,2.8,"Sunitinib","Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer","experiment",""
"BARRI0510_T2",0.52,0.45,0.02,0,0,244,2010,0,53,0.72,24.6,4.2,"Capecitabine","Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer","control",""
"BASEL0512_T1",0.687,0.296,0,0,0,115,2012,0,55.1,0.757,22.2,6.4,"Sorafenib plus Capecitabine population","Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer","experiment",""
"BASEL0512_T2",0.675,0.298,0,0,0,114,2012,0.009,54.4,0.737,20.9,4.1,"Placebo plus Capecitabine population","Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer","control",""
"BATIS0301_T1",0.36,0.51,0.13,0,0,142,2001,NA,55,0.71,19,NA,"MC","Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer","experiment",""
"BATIS0301_T2",0.42,0.45,0.13,0,0,155,2001,NA,54,0.61,16,NA,"AC","Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer","control",""
"BENNE1088_T1",0.28,0.396,0.323,0,0,167,1988,0,55,NA,12.57,NA,"CNF","A Randomized Multicenter Trial Comparing Mitoxantrone, Cyclophosphamide, and Fluorouracil With Doxorubicin, Cyclophosphamide, and Fluorouracil in the Therapy of Metastatic Breast Carcinoma","experiment",""
"BENNE1088_T2",0.267,0.416,0.317,0,0,164,1988,0,56,NA,12.83,NA,"CAF","A Randomized Multicenter Trial Comparing Mitoxantrone, Cyclophosphamide, and Fluorouracil With Doxorubicin, Cyclophosphamide, and Fluorouracil in the Therapy of Metastatic Breast Carcinoma","control",""
"BERGH0312_T1",0.56,0.42,0.01,0,0,296,2012,0,54,0.74,24.8,8.6,"Sunitinib + Docetaxel","First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study","experiment",""
"BERGH0312_T2",0.54,0.46,0,0,0,297,2012,0,56,0.7,25.5,8.3,"Docetaxel","First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study","control",""
"BERGH0612_T1",NA,NA,NA,NA,NA,258,2012,0,65,0.519,37.8,NA,"Anastrozole plus fulvestrant","FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer","experiment",""
"BERGH0612_T2",NA,NA,NA,NA,NA,256,2012,0,63,0.484,38.2,NA,"Anastrozole","FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer","control",""
"BISHO0899_T1",0.31,0.6,0.09,0,0,107,1999,0,54,0.75,17.3,5.3,"Paclitaxel","Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer","experiment",""
"BISHO0899_T2",0.4,0.48,0.12,0,0,102,1999,0,54,0.71,13.9,6.4,"CMFP","Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer","control",""
"BLACK0310_T1",0.47,0.49,0.04,0,0,148,2010,0,51,0.74,9.5,1.89,"Lapatinib","Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer","control",""
"BLACK0310_T2",0.54,0.41,0.05,0,0,148,2010,0,52,0.71,14,2.59,"Lapatinib Plus Trastuzumab","Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer","experiment",""
"BLAJM0399_T1",0.51,0.36,0.13,0,0,85,1999,0,54,0.494,17.3,NA,"FAC","A Prospective, Randomized Phase III Trial Comparing Combination Chemotherapy with Cyclophosphamide, Doxorubicin, and 5-Fluorouracil with Vinorelbine plus Doxorubicin in the Treatment of Advanced Breast Carcinoma","control",""
"BLAJM0399_T2",0.36,0.48,0.16,0,0,85,1999,0,53,0.565,17.8,NA,NA,"A Prospective, Randomized Phase III Trial Comparing Combination Chemotherapy with Cyclophosphamide, Doxorubicin, and 5-Fluorouracil with Vinorelbine plus Doxorubicin in the Treatment of Advanced Breast Carcinoma","experiment",""
"BLOHM0710_T1",0.65,0.35,0,0,0,111,2010,0,56,NA,19.9,NA,"EC","Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial","control",""
"BLOHM0710_T2",0.62,0.38,0,0,0,125,2010,0,57,NA,30,NA,"ED","Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial","experiment",""
"BLOMQ0393_T1",NA,NA,NA,0,0,83,1993,0,53.8,0.78,21.2,NA,"FEC Every 28 Days","Influence of Treatment Schedule on Toxicity and Efficacy of Cyclophosphamide, Epirubicin, and Fluorouracil in Metastatic Breast Cancer: A Randomized Trial Comparing Weekly and Every-4-Week Administration","control",""
"BLOMQ0393_T2",NA,NA,NA,0,0,83,1993,0,53.4,0.73,11.8,NA,"FEC Every 7 Days","Influence of Treatment Schedule on Toxicity and Efficacy of Cyclophosphamide, Epirubicin, and Fluorouracil in Metastatic Breast Cancer: A Randomized Trial Comparing Weekly and Every-4-Week Administration","experiment",""
"BOCCA1285_T1",NA,NA,NA,NA,NA,36,1985,0,60,0.333,20,NA,"Chemotherapy","Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer: A randomized study","control",""
"BOCCA1285_T2",NA,NA,NA,NA,NA,32,1985,0,61,0.496,34,NA,"Chemohormone therapy","Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer: A randomized study","experiment",""
"BONNE1102_T1",0.419,0.407,0.174,0,0,86,2002,0,54.9,NA,16,NA,"Docetaxel","Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure","experiment",""
"BONNE1102_T2",0.422,0.378,0.2,0,0,90,2002,0,54.55,NA,15,NA,"FUN","Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure","control",""
"BONNE1004_T1",0.61,0.36,0.03,0,0,70,2004,0,54,NA,34,NA,"ET","Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer","experiment",""
"BONNE1004_T2",0.72,0.24,0.04,0,0,72,2004,0,54,NA,28,NA,"FEC","Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer","control",""
"BONTE0698_T1",0.32,0.42,0.24,0,0,116,1998,0,56,0.42,10.97,NA,"Doxorubicin","Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer","control",""
"BONTE0698_T2",0.31,0.46,0.22,0,0,113,1998,0,56,0.49,10.27,NA,"Epirubicin","Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer","experiment",""
"BONTE1005_T1",0.54,0.42,0.03,0.01,0,108,2005,0,53,0.72,22.6,NA,"AT","Phase II to III Study Comparing Doxorubicin and Docetaxel With Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre","experiment",""
"BONTE1005_T2",0.53,0.4,0.07,0,0,107,2005,0,54,0.8,16.2,NA,"FAC","Phase II to III Study Comparing Doxorubicin and Docetaxel With Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre","control",""
"BRUFS0811_T1",0.606,0.394,0,0,0,94,2011,0,57.5,0.723,25,8.8,"PB","A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer","control",""
"BRUFS0811_T2",0.659,0.341,0,0,0,93,2011,0,55.2,0.71,24.3,11.3,"PB+G","A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer","experiment",""
"BUZDA0696_T1",0.43,0.38,0.17,0.02,0,195,1996,0,65,0.44,27.13,NA,"Protocol 03: Fadrozole HCL","Fadrozole HCL (CGS-16949A) versus Megestrol Acetate Treatment of Postmenopausal Patients with Metastatic Breast Cancer","experiment","A"
"BUZDA0696_T2",0.34,0.48,0.18,0,0,184,1996,0,68,0.48,23.07,NA,"Protocol 03: Megestrol Acetate","Fadrozole HCL (CGS-16949A) versus Megestrol Acetate Treatment of Postmenopausal Patients with Metastatic Breast Cancer","control","A"
"BUZDA0696_T3",0.44,0.43,0.12,0.01,0,150,1996,0,66.5,0.46,25.77,NA,"Protocol 06: Fadrozole HCL","Fadrozole HCL (CGS-16949A) versus Megestrol Acetate Treatment of Postmenopausal Patients with Metastatic Breast Cancer","experiment","B"
"BUZDA0696_T4",0.57,0.32,0.1,0,0,148,1996,0,65,0.45,27.9,NA,"Protocol 06: Megestrol Acetate","Fadrozole HCL (CGS-16949A) versus Megestrol Acetate Treatment of Postmenopausal Patients with Metastatic Breast Cancer","control","B"
"BYRNE0997_T1",0.314,0.543,0.124,0.019,0,109,1997,0,NA,NA,17.2,NA,"TAM + MPA","Medroxyprogesterone Acetate Addition or Substitution for Tamoxifen in Advanced Tamoxifen-Resistant Breast Cancer: A Phase III Randomized Trial","experiment",""
"BYRNE0997_T2",0.35,0.437,0.184,0.029,0,106,1997,0,NA,NA,18.4,NA,"MPA","Medroxyprogesterone Acetate Addition or Substitution for Tamoxifen in Advanced Tamoxifen-Resistant Breast Cancer: A Phase III Randomized Trial","control",""
"CHAN0409_T1",NA,NA,NA,NA,NA,152,2009,0,56,0.84,19.29,8.05,"GD","Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer","experiment",""
"CHAN0409_T2",NA,NA,NA,NA,NA,150,2009,0,53,0.88,21.45,7.98,"CD","Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer","control",""
"CONTE0387_T1",NA,NA,NA,NA,NA,59,1987,0,56,0.576,14.7,8.83,"CEF","Conventional Versus Cytokinetic Polychemotherapy With Estrogenic Recruitment in Metastatic Breast Cancer: Results of a Randomized Cooperative Trial","control",""
"CONTE0387_T2",NA,NA,NA,NA,NA,57,1987,0,57,0.517,18.6,9.2,"DES-CEF","Conventional Versus Cytokinetic Polychemotherapy With Estrogenic Recruitment in Metastatic Breast Cancer: Results of a Randomized Cooperative Trial","experiment",""
"CONTE0796_T1",0.554,0.313,0.094,0.039,0,128,1996,0,55,0.586,17.3,9.4,"CEF","Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO)","control",""
"CONTE0796_T2",0.554,0.308,0.107,0.031,0,130,1996,0,55,0.562,20,11,"DES-CEF","Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO)","experiment",""
"CONTE0804_T1",0.745,0.208,0.047,0,0,106,2004,0,58,0.754,20,11,"Concomitant arm A","Concomitant versus Sequential Administration of Epirubicin and Paclitaxel as First-Line Therapy in Metastatic Breast Carcinoma: Results from the Gruppo Oncologico Nord Ovest Randomized Trial","control",""
"CONTE0804_T2",0.783,0.196,0.022,0,0,92,2004,0,58,0.728,26,10.8,"Sequential arm B","Concomitant versus Sequential Administration of Epirubicin and Paclitaxel as First-Line Therapy in Metastatic Breast Carcinoma: Results from the Gruppo Oncologico Nord Ovest Randomized Trial","experiment",""
"DELEN0290_T1",NA,NA,NA,NA,NA,31,1990,0,63,0.225,NA,NA,"TAM","Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study","control",""
"DELEN0290_T2",NA,NA,NA,NA,NA,29,1990,0,66,0.14,34,NA,"TAM/MPA","Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study","experiment",""
"DELMA0401_T1",0.72,0.22,0.07,0,0,74,2001,0,57,0.49,32.7,NA,"CEF21","Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group","control",""
"DELMA0401_T2",0.62,0.26,0.12,0,0,77,2001,0,57,0.49,27.2,NA,"HD-CEF14","Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group","experiment",""
"DICKL0816_T1",0.618,0.376,0.006,0,0,173,2016,0,56,0.759,47.2,20.2,"Letrozole + Bevacizumab","Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)","experiment",""
"DICKL0816_T2",0.605,0.383,0.012,0,0,170,2016,0,59,0.743,43.9,15.6,"Letrozole","Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)","control",""
"DIERA0495_T1",0.39,0.51,0.1,0,0,41,1995,0,52,0.8,12.7,NA,"Paclitaxel","Phase II Randomized Study of Paclitaxel Versus Mitomycin in Advanced Breast Cancer","experiment",""
"DIERA0495_T2",0.45,0.4,0.15,0,0,40,1995,0,52.5,0.95,8.4,NA,"Mitomycin","Phase II Randomized Study of Paclitaxel Versus Mitomycin in Advanced Breast Cancer","control",""
"EJLER0604_T1",0.523,NA,NA,0,0,194,2004,0,55,0.49,18,8.2,"Epirubicin","Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403)","control",""
"EJLER0604_T2",0.526,NA,NA,0,0.005,193,2004,0,55,0.49,19.1,10.1,"VRL + Epirubicin","Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403)","experiment",""
"FRENC0488_T1",0.26,0.39,0.35,0,0,120,1988,0,54,NA,17.7,NA,"FAC","A Prospective Randomized Phase III Trial Comparing Combination Chemotherapy With Cyclophosphamide, Fluorouracil, and Either Doxorubicin or Epirubicin","control",""
"FRENC0488_T2",0.28,0.43,0.29,0,0,124,1988,0,54,NA,15,NA,"FEC","A Prospective Randomized Phase III Trial Comparing Combination Chemotherapy With Cyclophosphamide, Fluorouracil, and Either Doxorubicin or Epirubicin","experiment",""
"GENNA0806_T1",0.661,0.321,0.018,0,0,109,2006,0,56,0.532,28,NA,"Paclitaxel","Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer","experiment",""
"GENNA0806_T2",0.632,0.33,0.038,0,0,106,2006,0,56,0.443,29,NA,"Control","Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer","control",""
"GOSS0199_T1",0.373,0.475,0.097,0.04,0,225,1999,0,66,NA,26,NA,"Vorozole","Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer Patients","experiment",""
"GOSS0199_T2",0.462,0.37,0.123,0.039,0,227,1999,0,67,NA,28.7,NA,"Megestrole Acetate","Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer Patients","control",""
"GRADI0113_T1",0.45,0.51,NA,NA,NA,119,2013,NA,50.6,0.76,16.8,6.9,"Sorafenib + Paclitaxel","A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer","experiment",""
"GRADI0113_T2",0.44,0.55,NA,NA,NA,118,2013,NA,53.1,0.74,17.4,5.6,"Placebo + Paclitaxel","A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer","control",""
"HAMBE0411_T1",0.49,0.49,0.02,0,0,53,2011,0,50,0.7,30.5,9.4,"Combination Arm (H+D)","Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression as First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial","control",""
"HAMBE0411_T2",0.49,0.49,0.02,0,0,46,2011,0,54,0.58,19.7,3.9,"Sequential Arm (H -> D)","Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression as First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial","experiment",""
"HARBE0316_T1",0.61,0.387,0.003,0,0,332,2016,0,51.8,NA,20.5,5.5,"Afatinib group","Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial","experiment",""
"HARBE0316_T2",0.6,0.39,0.01,0,0,168,2016,0,53.1,NA,28.6,5.6,"Trastuzumab group","Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial","control",""
"HARBE0117_T1",0.51,0.43,0.06,0,0,105,2017,0,62,NA,23.3,NA,"PLD","A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study","experiment",""
"HARBE0117_T2",0.51,0.433,0.048,0.01,0,105,2017,0,63,NA,26.8,NA,"Capecitabine","A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study","control",""
"HARRI0102_T1",0.49,0.44,0.07,0,0,108,2002,NA,58,0.71,16,NA,"TLC D-99","Liposome-Encapsulated Doxorubicin Compared with Conventional Doxorubicin in a Randomized Multicenter Trial as First-Line Therapy of Metastatic Breast Carcinoma","experiment",""
"HARRI0102_T2",0.43,0.45,0.12,0,0,116,2002,NA,58,0.72,20,NA,"Doxorubicin","Liposome-Encapsulated Doxorubicin Compared with Conventional Doxorubicin in a Randomized Multicenter Trial as First-Line Therapy of Metastatic Breast Carcinoma","control",""
"HATSC0212_T1",NA,NA,NA,NA,NA,143,2012,0,57,NA,26,10.8,"ET","Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial","control",""
"HATSC0212_T2",NA,NA,NA,NA,NA,144,2012,0,55.7,NA,29.7,12.4,"TEX","Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial","experiment",""
"HENDE0589_T1",0.244,0.47,0.287,0,0,165,1989,0,55,0.4,9.1,NA,"Mitoxantrone","Randomized Clinical Trial Comparing Mitoxantrone With Doxorubicin in Previously Treated Patients With Metastatic Breast Cancer","experiment",""
"HENDE0589_T2",0.289,0.403,0.27,0.038,0,160,1989,0,55,0.4,8.93,NA,"Doxorubicin","Randomized Clinical Trial Comparing Mitoxantrone With Doxorubicin in Previously Treated Patients With Metastatic Breast Cancer","control",""
"ICLI0205_T1",0.208,0.521,0.271,0,0,96,2005,NA,47,NA,14,NA,"EoP","Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group","experiment",""
"ICLI0205_T2",0.175,0.464,0.361,0,0,97,2005,NA,49,NA,9.5,NA,"Paclitaxel","Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group","control",""
"INOUE0110_T1",0.77,0.23,0,0,0,53,2010,0,54.3,0.7,NA,14.6,"H + D","Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group","control",""
"INOUE0110_T2",0.74,0.26,0,0,0,54,2010,0,57.5,0.72,NA,3.7,"H -> H + D","Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group","experiment",""
"JASSL0301_T1",0.55,0.38,0.07,0,0,128,2001,0,50,0.64,23.3,NA,"AT","Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial","experiment",""
"JASSL0301_T2",0.47,0.46,0.07,0,0,131,2001,0,50,0.68,18.3,NA,"FAC","Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial","control",""
"JOHNS1109_T1",0.55,0.45,0,0,0,644,2009,0,63,NA,NA,10.8,"Letrozole + Placebo","Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer","control",""
"JOHNS1109_T2",0.58,0.42,0,0,0,642,2009,0,62,NA,NA,11.9,"Letrozole + Lapatinib","Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer","experiment",""
"KAUFM0400_T1",NA,NA,NA,NA,NA,366,2000,0,65,0.566,NA,NA,"EXE","Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial","experiment",""
"KAUFM0400_T2",NA,NA,NA,NA,NA,403,2000,0,65,0.593,28.79,NA,"MA","Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial","control",""
"KAUFM1109_T1",NA,NA,0,0,0,103,2009,0,56,NA,28.5,4.8,"Trastuzumab + Anastrozole","Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study","experiment",""
"KAUFM1109_T2",NA,NA,0,0,0,104,2009,0,54,NA,23.9,2.4,"Anastrozole Alone","Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study","control",""
"LANG0213_T1",0.68,0.26,0.05,0,0,285,2013,0.004,59,0.65,30.2,10.9,"Bevacizumab plus paclitaxel","Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial","control",""
"LANG0213_T2",0.65,0.33,0.03,0,0,279,2013,0.014,59,0.73,26.1,8.1,"Bevacizumab plus capecitabine","Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial","experiment",""
"LANGR1105_T1",0.34,0.49,0.16,0.02,0,353,2005,0,55,0.65,13,7,"EP","Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01","experiment",""
"LANGR1105_T2",0.35,0.49,0.14,0.02,0,352,2005,0,54,0.65,14,7.1,"EC","Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01","control",""
"LEO1010_T1",NA,NA,NA,NA,NA,361,2010,0,61,0.66,26.4,6.5,"Fulvestrant 500 mg","Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer","experiment",""
"LEO1010_T2",NA,NA,NA,NA,NA,374,2010,0,61,0.62,22.3,5.5,"Fulvestrant 250 mg","Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer","control",""
"MAVRO0110_T1",0.551,0.426,0.022,0,0,136,2010,0,60.5,NA,37.6,NA,"DE","Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer","control",""
"MAVRO0110_T2",0.485,0.485,0.029,0,0,136,2010,0,63,NA,35.7,NA,"DC","Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer","experiment",""
"MEHTA0812_T1",NA,NA,NA,0,0,345,2012,0,65,0.484,42,13.5,"Anastrozole alone","Combination anastrozole and fulvestrant in metastatic breast cancer","control",""
"MEHTA0812_T2",NA,NA,NA,0,0,349,2012,0,65,0.519,49.8,15,"Anastrozole and Fulvestrant","Combination anastrozole and fulvestrant in metastatic breast cancer","experiment",""
"MILES0117_T1",0.585,0.415,0,0,0,242,2017,NA,56,NA,25.8,8.8,"Placebo-paclitaxel","Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation","control",""
"MILES0117_T2",0.515,0.485,0,0,0,239,2017,NA,55,NA,28.8,11,"Bevacizumab + paclitaxel","Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation","experiment",""
"MILLN1207_T1",NA,NA,0,0,0,347,2007,0,56,0.795,26.7,11.8,"Paclitaxel plus Bevacizumab","Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer","experiment",""
"MILLN1207_T2",NA,NA,0,0,0,326,2007,0,55,0.871,25.2,5.9,"Paclitaxel","Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer","control",""
"MILLO0205_T1",0.5,0.5,0,0,0,230,2005,0,52,0.8,14.5,4.17,"Capecitabine","Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer","control",""
"MILLO0205_T2",0.504,0.491,0.004,0,0,232,2005,0,51,0.776,15.1,4.86,"Capecitabine + Bevacizumab","Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer","experiment",""
"MUSS0385_T1",0.33,0.54,0.09,0.03,0.01,69,1988,NA,63,NA,25.7,NA,"Megestrol Acetate","Megestrol Acetate Versus Tamoxifen in Advanced Breast Cancer: 5-Year Analysis-A Phase III Trial of the Piedmont Oncology Association","experiment",""
"MUSS0385_T2",0.22,0.57,0.15,0.04,0.01,67,1988,NA,62,NA,36,NA,"Tamoxifen ","Megestrol Acetate Versus Tamoxifen in Advanced Breast Cancer: 5-Year Analysis-A Phase III Trial of the Piedmont Oncology Association","control",""
"NAMER0601_T1",0.59,0.31,0.09,0,0,138,2001,0,60,0.81,20,7,"FAC or FEC","Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer","control",""
"NAMER0601_T2",0.53,0.39,0.08,0,0,142,2001,0,60,0.83,17,7,"MV","Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer","experiment",""
"NIELS0600_T1",NA,NA,NA,NA,0,81,2000,0,52,NA,15.2,NA,"Epirubicin","Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study","control",""
"NIELS0600_T2",NA,NA,NA,NA,0,74,2000,0,55,NA,20.6,NA,"Epirubicin + cisplatin","Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study","experiment",""
"NIELS1211_T1",NA,NA,0.109,0.006,0,170,2011,0,58,0.612,19.7,NA,"Gemcitabine + Docetaxel","Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group","experiment",""
"NIELS1211_T2",NA,NA,0.128,0,0,167,2011,0,58,0.533,17.9,NA,"Docetaxel","Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group","control",""
"OBRIE0304_T1",0.539,0.37,0.09,0,0,254,2004,0,59,0.586,21,6.9,"PLD","Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","experiment",""
"OBRIE0304_T2",0.49,0.396,0.109,0,0,255,2004,0,58,0.56,22,7.8,"Doxorubicin","Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","control",""
"OSHAU0901_T1",NA,NA,NA,NA,NA,61,2001,0,69,NA,19.6,NA,"Capecitabine","Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer","experiment",""
"OSHAU0901_T2",NA,NA,NA,NA,NA,32,2001,0,70,NA,17.2,NA,"CMF","Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer","control",""
"OSHAU0602_T1",NA,NA,NA,NA,NA,255,2002,0,52,NA,14.5,NA,"Capecitabine / Docetaxel","Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results","experiment",""
"OSHAU0602_T2",NA,NA,NA,NA,NA,256,2002,0,51,NA,11.5,NA,"Docetaxel","Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results","control",""
"OSHAU0111_T1",0.7,0.3,0,0,0,61,2011,0,56,NA,12.3,5.9,"Gemcitabine-Carboplatin and Iniparib","Iniparib plus chemotherapy in metastatic triple-negative breast cancer","experiment",""
"OSHAU0111_T2",0.68,0.32,0,0,0,62,2011,0,53,NA,7.7,3.6,"Gemcitabine-Carboplatin Alone","Iniparib plus chemotherapy in metastatic triple-negative breast cancer","control",""
"PACIL0506_T1",0.62,0.35,0.04,0,0,26,2006,0,51,0.54,18,NA,"ED","Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial","experiment",""
"PACIL0506_T2",0.64,0.36,0,0,0,25,2006,0,51,0.6,21,NA,"D","Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial","control",""
"PAGAN0217_T1",NA,NA,0.01,0,0,86,2017,0,53,0.67,35.6,NA,"Arm A","Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99","experiment",""
"PAGAN0217_T2",NA,NA,0,0,0,87,2017,0,57,0.65,36.3,NA,"Arm B","Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99","control",""
"PALLI0512_T1",0.419,0.541,0.041,0,0,74,2012,0,60,NA,20.4,5.4,"VG","A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer","experiment",""
"PALLI0512_T2",0.378,0.527,0.095,0,0,74,2012,0,60,NA,22.4,5.2,"Cap","A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer","control",""
"PAPAD0309_T1",0.71,0.21,0.09,0,0,30,2009,0,57,NA,28,NA,"Docetaxel","Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group","control",""
"PAPAD0309_T2",0.56,0.37,0.07,0,0,39,2009,0,57,NA,14,NA,"Docetaxel + gemcitabine","Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group","experiment",""
"PARIT0200_T1",0.42,0.5,0.08,0,0,166,2000,0,54,0.78,15.6,3.9,"Paclitaxel","Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over","experiment",""
"PARIT0200_T2",0.41,0.5,0.09,0,0,165,2000,0,55,0.75,18.3,7.5,"Doxorubicin","Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over","control",""
"PARK0513_T1",0.504,0.478,0.017,0,0,116,2013,0,48,0.698,32.3,7.5,"Maintenance","Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02","experiment",""
"PARK0513_T2",0.491,0.491,0.017,0,0,115,2013,0,47,0.643,23.5,3.8,"Observation","Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02","control",""
"PARK1117_T1",0.424,0.509,0.068,0,0,59,2017,0,50,0.746,21.2,9.6,"EG","Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer","experiment",""
"PARK1117_T2",0.441,0.525,0.034,0,0,59,2017,0,50,0.712,NA,12.6,"PG","Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer","control",""
"PAVES0395_T1",0.493,0.437,0.07,0,0,78,1995,0,NA,0.211,19,NA,"FEC","Epirubicin versus Mitoxantrone in Combination Chemotherapy for Metastatic Breast Cancer","experiment",""
"PAVES0395_T2",0.486,0.429,0.086,0,0,74,1995,0,NA,0.214,15.5,NA,"FNC","Epirubicin versus Mitoxantrone in Combination Chemotherapy for Metastatic Breast Cancer","control",""
"POWLE0684_T1",NA,NA,NA,NA,NA,111,1984,0,NA,NA,10,NA,"TAD","Treatment of Disseminated Breast Cancer with Tamoxifen, Aminoglutethimide, Hydrocortisone, and Danazol, Used in Combination or Sequentially","experiment",""
"POWLE0684_T2",NA,NA,NA,NA,NA,111,1984,0,NA,NA,10,NA,"T","Treatment of Disseminated Breast Cancer with Tamoxifen, Aminoglutethimide, Hydrocortisone, and Danazol, Used in Combination or Sequentially","control",""
"RIVER0408_T1",NA,NA,NA,0,0,62,2008,NA,56,NA,18.3,5.7,"Every-3-week treatment arm","Phase 3 Study Comparing the Use of Docetaxel on an Every-3-week Versus Weekly Schedule in the Treatment of Metastatic Breast Cancer","control",""
"RIVER0408_T2",NA,NA,NA,0,0,63,2008,NA,54,NA,18.6,5.5,"Weekly treatment arm","Phase 3 Study Comparing the Use of Docetaxel on an Every-3-week Versus Weekly Schedule in the Treatment of Metastatic Breast Cancer","experiment",""
"ROBER0606_T1",0.6,0.36,0.04,0,0,98,2006,0,55,0.53,35.7,10.7,"TPC","Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer","experiment",""
"ROBER0606_T2",0.61,0.36,0.03,0,0,98,2006,0,56,0.4,32.2,7.1,"TP","Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer","control",""
"ROBER0411_T1",0.56,0.432,0.008,0,0,242,2011,NA,57,NA,17.6,7.4,"Sunitinib + Paclitaxel","Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial","experiment",""
"ROBER0411_T2",0.59,0.39,0.02,0,0,243,2011,NA,57,NA,NA,9.2,"Bevacizumab + Paclitaxel","Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial","control",""
"SJOST0899_T1",0.32,0.57,0.12,0,0,143,1999,0,50,0.73,10.4,NA,"Docetaxel","Docetaxel Compared with Sequential Methotrexate and 5-Fluorouracil in Patients with Advanced Breast Cancer after Anthracycline Failure: a Randomised Phase III Study with Crossover on Progression by the Scandinavian Breast Group","experiment",""
"SJOST0899_T2",0.27,0.57,0.16,0,0,139,1999,0,51,0.69,11,NA,"MF","Docetaxel Compared with Sequential Methotrexate and 5-Fluorouracil in Patients with Advanced Breast Cancer after Anthracycline Failure: a Randomised Phase III Study with Crossover on Progression by the Scandinavian Breast Group","control",""
"SLAMO0301_T1",NA,NA,NA,NA,NA,143,2001,0,54,0.76,26.8,NA,"An Anthracycline, Cyclophosphamide, and Trastuzumab","Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2","experiment","A"
"SLAMO0301_T2",NA,NA,NA,NA,NA,138,2001,0,54,0.71,21.4,NA,"An Anthracycline and Cyclophosphamide Alone","Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2","control","A"
"SLAMO0301_T3",NA,NA,NA,NA,NA,92,2001,0,51,0.65,22.1,NA,"Paclitaxel and Trastuzumab","Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2","experiment","B"
"SLAMO0301_T4",NA,NA,NA,NA,NA,96,2001,0,51,0.71,18.4,NA,"Paclitaxel Alone","Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer that Overexpresses HER2","control","B"
"SPARA1204_T1",0.65,0.35,0,0,0,114,2004,0,56,NA,24.7,4.7,"Marimastat","Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196","experiment",""
"SPARA1204_T2",0.42,0.58,0,0,0,65,2004,0,58,NA,26.6,3.1,"Placebo","Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196","control",""
"SPARA0909_T1",0.43,0.5,0.08,0,0,373,2009,0,51.8,NA,20.6,7,"Docetaxel ","Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study","control",""
"SPARA0909_T2",0.42,0.5,0.08,0,0,377,2009,0,52.5,NA,20.5,9.8,"PLD + Docetaxel","Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study","experiment",""
"SPARA0710_T1",NA,NA,NA,NA,NA,595,2010,0,53,NA,16.4,6.2,"Ixabepilone Plus Capecitabine","Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane","experiment",""
"SPARA0710_T2",NA,NA,NA,NA,NA,603,2010,0,53,NA,15.6,4.4,"Capecitabine","Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane","control",""
"STEMM0310_T1",NA,NA,NA,NA,NA,48,2010,0,73,NA,22.7,NA,"q1w","Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer","experiment",""
"STEMM0310_T2",NA,NA,NA,NA,NA,54,2010,0,70.5,NA,15.8,NA,"q3w","Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer","control",""
"STEMM0310b_T1",NA,NA,NA,NA,NA,43,2010,0,54,NA,20.5,NA,"q1w","Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer","experiment",""
"STEMM0310b_T2",NA,NA,NA,NA,NA,42,2010,0,56,NA,28.7,NA,"q3w","Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer","control",""
"VALER0111_T1",NA,NA,NA,NA,NA,131,2011,0,52,0.664,37.1,NA,"TH","Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens","control",""
"VALER0111_T2",NA,NA,NA,NA,NA,132,2011,0,51,0.583,37.4,NA,"TCH","Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens","experiment",""
"VERMA1112_T1",0.64,0.36,0,0,0,488,2012,NA,53,0.68,25.9,6.4,"Lapatinib plus Capecitabine","Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","control",""
"VERMA1112_T2",0.61,0.39,0,0,0,490,2012,NA,53,0.67,29.9,9.6,"T-DM1","Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","experiment",""
"WILDI0910_T1",0.267,0.733,0,0,0,36,2010,0,58,0.86,12,2.8,"Arm A (Sunitinib)","Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.","experiment",""
"WILDI0910_T2",0.5,0.5,0,0,0,19,2010,0,59,0.74,18.9,3.1,"Arm B (No therapy)","Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.","control",""
"WOLFF0113_T1",NA,NA,NA,NA,NA,555,2013,0,63,NA,NA,8.9,"Letrozole Plus Temsirolimus","Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","experiment",""
"WOLFF0113_T2",NA,NA,NA,NA,NA,555,2013,0,63,NA,NA,9,"Letrozole Plus Placebo","Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","control",""
"YAMAM0217_T1",0.817,0.183,0,0,0,82,2017,0,56.5,NA,33.8,10.5,"XT","Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline- pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial","experiment",""
"YAMAM0217_T2",0.765,0.235,0,0,0,81,2017,0,57,NA,28.8,9.8,"T -> X","Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline- pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial","control",""
"ZHANG0317_T1",0.34,0.638,0.022,0,0,270,2017,0,50,0.803,16.13,8.44,"Utidelone plus capecitabine","Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial","experiment",""
"ZHANG0317_T2",0.291,0.679,0.03,0,0,135,2017,0,50,0.821,12.78,4.27,"Capecitabine alone","Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial","control",""
